{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+Oxycodone&page=2",
    "query": {
      "intervention": "Placebo and Oxycodone",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 119,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+Oxycodone&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+and+Oxycodone&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T14:27:57.030Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05567354",
      "title": "A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recreational Drug Use"
      ],
      "interventions": [
        {
          "name": "PF614",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ensysce Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 27,
      "start_date": "2022-06-10",
      "completion_date": "2022-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-09-30T14:27:57.030Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05567354"
    },
    {
      "nct_id": "NCT03996694",
      "title": "Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Depression"
      ],
      "interventions": [
        {
          "name": "Belbuca 300 µg",
          "type": "DRUG"
        },
        {
          "name": "Belbuca 600 µg",
          "type": "DRUG"
        },
        {
          "name": "Belbuca 900 µg",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone 60 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioDelivery Sciences International",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 19,
      "start_date": "2019-07-23",
      "completion_date": "2019-10-27",
      "has_results": true,
      "last_update_posted_date": "2021-02-05",
      "last_synced_at": "2026-09-30T14:27:57.030Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03996694"
    },
    {
      "nct_id": "NCT02929589",
      "title": "Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain",
        "Hernia"
      ],
      "interventions": [
        {
          "name": "Ibuprofen",
          "type": "DRUG"
        },
        {
          "name": "Opioid Medication",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ibuprofen + Opioid medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mike O'Callaghan Military Hospital",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2018-07-05",
      "completion_date": "2021-08-23",
      "has_results": true,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-09-30T14:27:57.030Z",
      "location_count": 1,
      "location_summary": "Nellis Air Force Base, Nevada",
      "locations": [
        {
          "city": "Nellis Air Force Base",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02929589"
    },
    {
      "nct_id": "NCT01740414",
      "title": "Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Abuse",
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "MN-166 (50 mg) First",
          "type": "DRUG"
        },
        {
          "name": "Placebo First",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2012-11",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-09-30T14:27:57.030Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01740414"
    },
    {
      "nct_id": "NCT05142267",
      "title": "Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Back Pain",
        "Stress"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone",
          "type": "DRUG"
        },
        {
          "name": "Naloxone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2022-03-02",
      "completion_date": "2026-04-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-30T14:27:57.030Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05142267"
    },
    {
      "nct_id": "NCT04218409",
      "title": "Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "OxyCODONE 5 mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Oxytocin nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oxycodone",
          "type": "OTHER"
        },
        {
          "name": "Placebo oxytocin",
          "type": "OTHER"
        },
        {
          "name": "OxyCODONE 2.5 mg Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 45,
      "start_date": "2021-09-02",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-09-30T14:27:57.030Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04218409"
    },
    {
      "nct_id": "NCT01330459",
      "title": "Hydrocodone For Pain Control in First Trimester Surgical Abortion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Hydrocodone/acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ibuprofen",
          "type": "DRUG"
        },
        {
          "name": "Lorazepam",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elizabeth Micks",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 121,
      "start_date": "2011-02",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2019-04-26",
      "last_synced_at": "2026-09-30T14:27:57.030Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01330459"
    },
    {
      "nct_id": "NCT05256108",
      "title": "Assessment of Abuse Potential of Cebranopadol in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Abuse Potential"
      ],
      "interventions": [
        {
          "name": "Oxycodone 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Tramadol 600 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cebranopadol 600 µg",
          "type": "DRUG"
        },
        {
          "name": "Cebranopadol 1000 µg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 38,
      "start_date": "2022-03-28",
      "completion_date": "2022-07-12",
      "has_results": false,
      "last_update_posted_date": "2022-07-27",
      "last_synced_at": "2026-09-30T14:27:57.030Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05256108"
    },
    {
      "nct_id": "NCT01395784",
      "title": "Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Abuse"
      ],
      "interventions": [
        {
          "name": "pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 32,
      "start_date": "2010-08",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-02-23",
      "last_synced_at": "2026-09-30T14:27:57.030Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01395784"
    },
    {
      "nct_id": "NCT02218021",
      "title": "A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Samidorphan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkermes, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 59,
      "start_date": "2014-08",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2014-12-02",
      "last_synced_at": "2026-09-30T14:27:57.030Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02218021"
    }
  ]
}